Brigatinib in ROS1 NSCLC

Stephen V Liu shared a post on X:

”Brigatinib in ROS1 NSCLC (Phase II Barossa study) at The Open Access journal of ESMO. RR 71.4% first-line and RR 31.6% post crizotinib. mPFS 12m first-line and 7.3m post-crizotinib. Activity seen here, but better options now exist (repotrectinib, NVL-520).”

Read further.
Source: Stephen V Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.